Υπήρξε ένα πρόβλημα κατά τη φόρτωση αυτής της σελίδας.
Η ομάδα μας έχει ειδοποιηθεί, αλλά επικοινωνήστε μαζί μας χρησιμοποιώντας το widget υποστήριξης email εάν το πρόβλημα παραμένει.
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | Yes | No |
| Is net profit margin increasing? | Yes | No |
| Is asset turnover increasing? | Yes | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| Exelixis, Inc. |
| BioCryst Pharmaceuticals, Inc. |
| BridgeBio Pharma, Inc. |
| Moderna, Inc. |
| BioMarin Pharmaceutical Inc. |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| EXEL | BCRX | BBIO | MRNA | BMRN | ISI | |||
| Return On Equity | ||||||||
| Latest Twelve Months | 30% | 12% | 50% | -29% | 10% | -119% | ||
| Fiscal Year - 1 | 9% | 60% | 49% | -29% | 4% | -76% | ||
| Fiscal Year - 2 | 8% | 123% | 45% | 50% | 3% | -40% | ||
| Fiscal Year - 3 | 11% | 292% | 138% | 146% | -2% | -4% | ||
| Fiscal Year - 4 | 6% | -1925% | -192% | -40% | 24% | -40% | ||
| Fiscal Year - 5 | 22% | -249% | -72% | -38% | -1% | 22% | ||
| Average | 14% | -281% | 3% | 10% | 6% | -43% | ||
| Median | 10% | 36% | 47% | -29% | 3% | -40% | ||
| Benchmarks | Ticker | |||||||
| Exelixis, Inc. | NasdaqGS:EXEL | |||||||
| BioCryst Pharmaceuticals, Inc. | NasdaqGS:BCRX | |||||||
| BridgeBio Pharma, Inc. | NasdaqGS:BBIO | |||||||
| Moderna, Inc. | NasdaqGS:MRNA | |||||||
| BioMarin Pharmaceutical Inc. | NasdaqGS:BMRN | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | EXEL | BCRX | BBIO | MRNA | BMRN | ISI | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | ||
| Revenues | ||||||||
| Latest Twelve Months | 2,299 | 503 | 127 | 3,177 | 2,950 | 717 | ||
| Fiscal Year | 2,169 | 451 | 222 | 3,236 | 2,854 | 705 | ||
| Fiscal Year - 1 | 1,830 | 331 | 9 | 6,848 | 2,419 | 788 | ||
| Fiscal Year - 2 | 1,611 | 271 | 78 | 19,263 | 2,096 | 587 | ||
| Fiscal Year - 3 | 1,435 | 157 | 70 | 18,471 | 1,846 | 810 | ||
| Fiscal Year - 4 | 988 | 18 | 8 | 803 | 1,860 | 729 | ||
| Fiscal Year - 5 | 968 | 49 | 41 | 60 | 1,704 | 1,123 | ||
| Net Income | ||||||||
| Latest Twelve Months | 644 | (53) | (668) | (3,357) | 524 | (458) | ||
| Fiscal Year | 521 | (89) | (536) | (3,561) | 427 | (454) | ||
| Fiscal Year - 1 | 208 | (227) | (643) | (4,714) | 168 | (366) | ||
| Fiscal Year - 2 | 182 | (247) | (481) | 8,362 | 142 | (270) | ||
| Fiscal Year - 3 | 231 | (184) | (563) | 12,202 | (64) | (29) | ||
| Fiscal Year - 4 | 112 | (183) | (449) | (747) | 854 | (444) | ||
| Fiscal Year - 5 | 321 | (109) | (261) | (514) | (24) | 281 | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 2,804 | 468 | 849 | 16,729 | 6,873 | 2,764 | ||
| Latest Fiscal Quarter | 2,837 | 480 | 882 | 12,704 | 7,147 | 2,813 | ||
| Fiscal Year | 2,948 | 490 | 919 | 14,142 | 6,989 | 3,004 | ||
| Fiscal Year - 1 | 2,942 | 517 | 546 | 18,426 | 6,842 | 2,990 | ||
| Fiscal Year - 2 | 3,071 | 550 | 623 | 25,858 | 6,375 | 2,534 | ||
| Fiscal Year - 3 | 2,616 | 588 | 1,013 | 24,669 | 6,005 | 2,612 | ||
| Fiscal Year - 4 | 2,137 | 335 | 704 | 7,337 | 5,848 | 2,390 | ||
| Fiscal Year - 5 | 1,886 | 175 | 632 | 1,589 | 4,690 | 3,233 | ||
| Fiscal Year - 6 | 1,422 | 147 | 465 | 1,962 | 4,427 | 2,668 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 2,128 | (476) | (1,050) | 12,817 | 5,074 | 297 | ||
| Latest Fiscal Quarter | 2,131 | (452) | (1,648) | 10,066 | 5,793 | 476 | ||
| Fiscal Year | 2,244 | (476) | (1,468) | 10,901 | 5,658 | 588 | ||
| Fiscal Year - 1 | 2,264 | (456) | (1,354) | 13,854 | 4,952 | 387 | ||
| Fiscal Year - 2 | 2,488 | (295) | (1,255) | 19,123 | 4,603 | 573 | ||
| Fiscal Year - 3 | 2,211 | (107) | (870) | 14,145 | 4,266 | 772 | ||
| Fiscal Year - 4 | 1,879 | (19) | 58 | 2,561 | 4,106 | 743 | ||
| Fiscal Year - 5 | 1,686 | 38 | 408 | 1,175 | 3,122 | 1,471 | ||
| Fiscal Year - 6 | 1,287 | 49 | 315 | 1,530 | 2,968 | 1,048 | ||